Johannes Levin1, Alexander Kurz, Thomas Arzberger, Armin Giese, Günter U Höglinger. 1. Department of Neurology, Klinikum rechts der Isar, Technische Universität München and Chair for Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Department of Neurology, Ludwig-Maximilians-Universität München, German Center for Neurodegenerative Diseases (DZNE), Munich, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Center for Neuropathology and Prion Research (ZNP), Ludwig-Maximilians-Universität München, Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München.
Abstract
BACKGROUND: Aside from idiopathic Parkinson syndrome (Parkinson's disease), there are a number of other, so-called atypical parkinsonian syndromes: dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). DLB is a common disease, with a prevalence of 0.4% (400 cases per 100 000 persons) in the elderly; MSA and PSP both have a prevalence of 5 to 10 per 100 000 persons, while the prevalence of CBD is about 1 per 100 000. METHODS: This review is based on pertinent publications retrieved by a selective literature search. RESULTS: The atypical parkinsonian syndromes are synucleinopathies and tauopathies, i.e., disorders characterized by the abnormal deposition of the proteins α-synuclein and tau. The site of deposition is correlated with the clinical features. In DLB, synuclein is mainly deposited in neocortical neurons, with some brain stem involvement as well. The main clinical features are dementia and, later on, parkinsonism. In MSA, synuclein is deposited in oligodendrocytes, mainly in the cerebellum but also in the brain stem; the main clinical feature is autonomic dysfunction combined with parkinsonism or cerebellar ataxia. Synucleinopathies often impair REM (rapid eye movement) sleep. PSP and CBD, on the other hand, are primary tauopathies. PSP usually causes predominantly supranuclear vertical gaze palsy and early postural instability with falls, less commonly parkinsonism (PSP-P) or frontotemporal dementia (PSP-FTD) as its most prominent feature. CBD typically manifests itself as markedly asymmetrical parkinsonism with apraxia or cortical sensory disturbance. At present, there is no accepted causal treatment for any of these disorders; the available symptomatic treatments are of limited efficacy and are supported only by low-level evidence. CONCLUSION: Causal treatments for neurodegenerative diseases are now being developed and tested, and thus a molecular diagnosis is desirable. This will require the cooperation of primary care physicians with specialized centers.
BACKGROUND: Aside from idiopathic Parkinson syndrome (Parkinson's disease), there are a number of other, so-called atypical parkinsonian syndromes: dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). DLB is a common disease, with a prevalence of 0.4% (400 cases per 100 000 persons) in the elderly; MSA and PSP both have a prevalence of 5 to 10 per 100 000 persons, while the prevalence of CBD is about 1 per 100 000. METHODS: This review is based on pertinent publications retrieved by a selective literature search. RESULTS: The atypical parkinsonian syndromes are synucleinopathies and tauopathies, i.e., disorders characterized by the abnormal deposition of the proteins α-synuclein and tau. The site of deposition is correlated with the clinical features. In DLB, synuclein is mainly deposited in neocortical neurons, with some brain stem involvement as well. The main clinical features are dementia and, later on, parkinsonism. In MSA, synuclein is deposited in oligodendrocytes, mainly in the cerebellum but also in the brain stem; the main clinical feature is autonomic dysfunction combined with parkinsonism or cerebellar ataxia. Synucleinopathies often impair REM (rapid eye movement) sleep. PSP and CBD, on the other hand, are primary tauopathies. PSP usually causes predominantly supranuclear vertical gaze palsy and early postural instability with falls, less commonly parkinsonism (PSP-P) or frontotemporal dementia (PSP-FTD) as its most prominent feature. CBD typically manifests itself as markedly asymmetrical parkinsonism with apraxia or cortical sensory disturbance. At present, there is no accepted causal treatment for any of these disorders; the available symptomatic treatments are of limited efficacy and are supported only by low-level evidence. CONCLUSION: Causal treatments for neurodegenerative diseases are now being developed and tested, and thus a molecular diagnosis is desirable. This will require the cooperation of primary care physicians with specialized centers.
Authors: Martin Köllensperger; Felix Geser; Klaus Seppi; Michaela Stampfer-Kountchev; Martin Sawires; Christoph Scherfler; Sylvia Boesch; Joerg Mueller; Vasiliki Koukouni; Niall Quinn; Maria Teresa Pellecchia; Paolo Barone; Nicole Schimke; Richard Dodel; Wolfgang Oertel; Erik Dupont; Karen Østergaard; Christine Daniels; Günther Deuschl; Tanya Gurevich; Nir Giladi; Miguel Coelho; Cristina Sampaio; Christer Nilsson; Håkan Widner; Francesca Del Sorbo; Alberto Albanese; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Christoph Kamm; Thomas Gasser; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Anette Schrag; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2008-06-15 Impact factor: 10.338
Authors: Robert Perneczky; Alexander Drzezga; Henning Boecker; Hans Förstl; Alexander Kurz; Peter Häussermann Journal: Dement Geriatr Cogn Disord Date: 2008-05-14 Impact factor: 2.959
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat Journal: Dtsch Arztebl Int Date: 2019-11-01 Impact factor: 5.594
Authors: Wolfgang H Jost; Paul Lingor; Lars Tönges; Johannes Schwarz; Carsten Buhmann; Jan Kassubek; Anette Schrag Journal: J Neural Transm (Vienna) Date: 2019-05-13 Impact factor: 3.575